164 related articles for article (PubMed ID: 33729581)
1. Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting.
Kostos L; Hong W; Lee B; Tran B; Lok SW; Anton A; Gard G; To YH; Wong V; Shapiro J; Wong R; Wong S; de Boer R; Gibbs P
Int J Cancer; 2021 Jul; 149(2):409-419. PubMed ID: 33729581
[TBL] [Abstract][Full Text] [Related]
2. Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
Westgeest HM; Uyl-de Groot CA; van Moorselaar RJA; de Wit R; van den Bergh ACM; Coenen JLLM; Beerlage HP; Hendriks MP; Bos MMEM; van den Berg P; van de Wouw AJ; Spermon R; Boerma MO; Geenen MM; Tick LW; Polee MB; Bloemendal HJ; Cordia I; Peters FPJ; de Vos AI; van den Bosch J; van den Eertwegh AJM; Gerritsen WR
Eur Urol Focus; 2018 Sep; 4(5):694-701. PubMed ID: 28753794
[TBL] [Abstract][Full Text] [Related]
3. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.
Westgeest HM; Kuppen MCP; van den Eertwegh AJM; de Wit R; Coenen JLLM; van den Berg HPP; Mehra N; van Oort IM; Fossion LMCL; Hendriks MP; Bloemendal HJ; van de Luijtgaarden ACM; Ten Bokkel Huinink D; van den Bergh ACMF; van den Bosch J; Polee MB; Weijl N; Bergman AM; Uyl-de Groot CA; Gerritsen WR
Clin Genitourin Cancer; 2019 Oct; 17(5):e946-e956. PubMed ID: 31439536
[TBL] [Abstract][Full Text] [Related]
4. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry.
Chowdhury S; Bjartell A; Lumen N; Maroto P; Paiss T; Gomez-Veiga F; Birtle A; Kramer G; Kalinka E; Spaëth D; Feyerabend S; Matveev V; Lefresne F; Lukac M; Wapenaar R; Costa L
Target Oncol; 2020 Jun; 15(3):301-315. PubMed ID: 32500294
[TBL] [Abstract][Full Text] [Related]
5. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
6. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.
Baillie K; Mueller T; Pan J; Laskey J; Bennie M; Crearie C; Kavanagh K; Alvarez-Madrazo S; Morrison D; Clarke J; Keel A; Cameron D; Wu O; Kurdi A; Jones RJ
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):653-663. PubMed ID: 32316077
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T
BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
9. Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden.
Svensson J; Andersson E; Persson U; Edekling T; Ovanfors A; Ahlgren G
Scand J Urol; 2016 Aug; 50(4):286-91. PubMed ID: 27109827
[TBL] [Abstract][Full Text] [Related]
10. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
11. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract][Full Text] [Related]
13. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
14. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
15. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
16. Assessment of a Clinical Trial-Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer.
Coquet J; Bievre N; Billaut V; Seneviratne M; Magnani CJ; Bozkurt S; Brooks JD; Hernandez-Boussard T
JAMA Netw Open; 2021 Jan; 4(1):e2031730. PubMed ID: 33481032
[TBL] [Abstract][Full Text] [Related]
17. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
[TBL] [Abstract][Full Text] [Related]
18. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region.
Maruzzo M; Basso U; Borsatti E; Evangelista L; Alongi F; Caffo O; Maines F; Galuppo S; De Vivo R; Zustovich F; Palleschi D; Zivi A; Sava T; Sorarù M; Iacovelli R; Nicodemo M; Baier S; Fratino L; Zagonel V
Clin Genitourin Cancer; 2019 Feb; 17(1):e187-e194. PubMed ID: 30448106
[TBL] [Abstract][Full Text] [Related]
19. Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.
Poon DMC; Wong KCW; Chan TW; Law K; Chan K; Lee EKC; Lee C; Chan M;
Clin Genitourin Cancer; 2018 Oct; 16(5):402-412.e1. PubMed ID: 30126765
[TBL] [Abstract][Full Text] [Related]
20. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
